The PIPE provides near-term cash runway to fund the Phase 1/2 TNBC trial start, but the ~$5.6M is modest for a clinical-stage biotech. Monitor for the filing of the resale registration statement (due within 30 days) and any early clinical data readouts from the Telomir-Zn program, which are the primary catalysts.
Price Chart
Executive Summary
Telomir Pharmaceuticals closed a ~$5.6M PIPE financing on October 5, 2026, issuing 4,843,300 common shares at $1.16/share (a 5% discount to 10-day VWAP) to accredited investors, including an additional $1.0M from existing significant shareholder John Paul DeJoria. The financing includes no investor warrants or variable-pricing features, but the placement agent (Alexander Capital) received a cash fee of ~$455,000 and warrants to purchase 387,464 shares at $1.16. Proceeds will fund clinical development of Telomir-Zn (Phase 1/2 in triple-negative breast cancer) and working capital.
Key Financial Metrics
Key Facts
- Closed PIPE of 4,843,300 common shares at $1.16/share for ~$5.6M gross proceeds.
- John Paul DeJoria invested an additional $1.0M; other existing and new investors participated.
- No investor warrants, convertible securities, or variable-price/reset features were issued.
- Placement agent Alexander Capital received ~$455,000 cash fee (9.0% of gross) and 387,464 warrants at $1.16/share (8.0% of shares sold).
- Proceeds primarily support Phase 1/2 clinical trial of Telomir-Zn in advanced/metastatic triple-negative breast cancer.
- Registration rights agreement requires filing a resale registration statement within 30 days of closing.
- 90-day lock-up on further equity issuances (with standard exceptions) from closing date.
Financial Impact
~$5.6M gross proceeds raised; dilution of ~4.84M new shares (plus up to 387,464 warrant shares for placement agent).
Risk Factors
- Dilution of ~4.84M new shares plus up to 387,464 placement agent warrants.
- Modest capital raise may require additional financing before meaningful clinical data is generated.
- Clinical-stage biotech risk: Telomir-Zn has not yet demonstrated human efficacy or safety.
- Potential overhang from resale registration statement filing (within 30 days) enabling investor selling.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-045860 |
| Exhibit: ex10-2.htm | 0001493152-26-045860 |
| Exhibit: ex4-1.htm | 0001493152-26-045860 |
| Exhibit: ex99-1.htm | 0001493152-26-045860 |
| Document: form8-k.htm | 0001493152-26-045860 |
| Document: 0001493152-26-045860-index-headers.html | 0001493152-26-045860 |
| Document: 0001493152-26-045860-index.html | 0001493152-26-045860 |
| Document: 0001493152-26-045860.txt | 0001493152-26-045860 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $1.20 | awaiting T+20 | — | $1.03 (−14.17%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $1.03 (−8.04%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $1.03 (−8.04%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $1.03 (−11.97%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $1.03 (−11.97%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $1.03 (−11.97%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $1.03 (−20.16%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $1.03 (−14.88%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $1.03 (−26.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers